Tarsus Pharmaceuticals Q2 EPS $(1.17) Down From $(0.24) YoY
Portfolio Pulse from Benzinga Newsdesk
Tarsus Pharmaceuticals reported Q2 losses of $(1.17) per share, a 387.5% decrease from the same period last year when losses were $(0.24) per share.
August 10, 2023 | 9:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Tarsus Pharmaceuticals reported a significant increase in losses for Q2, with EPS at $(1.17), a 387.5% decrease YoY.
Tarsus Pharmaceuticals reported a significant increase in losses for Q2, which is likely to negatively impact investor sentiment and potentially lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100